HIV Vaccine Research and Design (HIVRAD) Program (P01 Clinical Trial Not Allowed)
ID: 350461Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $3M

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/350461

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-037.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity through the HIV Vaccine Research and Design (HIVRAD) Program, aimed at supporting multi-disciplinary projects focused on the discovery of effective prophylactic vaccines against HIV/AIDS. This initiative encourages comprehensive research addressing critical scientific questions related to immune responses, vaccine vectors, and the evaluation of vaccine concepts in non-human primate models. The program anticipates funding 1-2 awards with a total budget of approximately $5 million for fiscal year 2025, with projects eligible for a maximum duration of five years. Interested applicants must comply with the NIH Data Management and Sharing Policy and submit their applications by March 13, 2026. For further information, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-24-037.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-037-Full-Announcement.html
    PAR-24-037.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is announcing the HIV Vaccine Research and Design (HIVRAD) Program intended to support comprehensive projects focused on developing effective prophylactic vaccines against HIV/AIDS. This Notice of Funding Opportunity (NOFO) encourages multi-disciplinary research addressing critical questions in vaccine discovery. It aims to investigate various aspects such as immune responses, vaccine vectors, and the use of non-human primate models. Eligible entities include higher education institutions, nonprofits, and various government entities. The program will fund 1-2 awards with a budget totaling approximately $5 million for fiscal year 2025, supporting projects for a maximum of five years. Applications must comply with the NIH Data Management and Sharing Policy, include a specific Plan for Enhancing Diverse Perspectives (PEDP), and are due by specified deadlines. The overall impact rating will consider significance, innovation, investigator qualifications, and project approach, ensuring a collaborative and scientific environment conducive to groundbreaking research. This initiative reflects NIH's ongoing commitment to addressing public health needs related to HIV prevention through robust scientific inquiry and innovation.
    Similar Opportunities
    Implementation Science to End the HIV Epidemic
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Implementation Science to End the HIV Epidemic," aimed at advancing efforts to combat HIV through innovative research-community collaborations. The initiative seeks projects that will develop and evaluate strategies for HIV prevention, diagnosis, treatment, and outbreak response, particularly in communities disproportionately affected by the epidemic. This funding, totaling an estimated $7 million, will support approximately 10 awards, with applications open to a diverse range of eligible entities, including tribal governments, federal agencies, and community-based organizations. Interested applicants should note that the estimated synopsis close date is April 17, 2026, and the anticipated award date is December 1, 2026; for further inquiries, contact Rebecca Mandt, Ph.D., at rebecca.mandt@nih.gov or call 301-435-7695.
    Rational Design of Vaccines Against Hepatitis C Virus (U19 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Rational Design of Vaccines Against Hepatitis C Virus (U19 Clinical Trial Not Allowed)" aimed at supporting the development of broadly protective vaccines for hepatitis C virus (HCV). This initiative seeks to establish a consortium of Research Centers that will focus on the design, optimization, evaluation, and advancement of vaccine candidates into clinical trials, encouraging collaborative investigations among experts in HCV vaccine development. The estimated total program funding is $8.3 million, with four awards expected, and interested applicants are encouraged to prepare their proposals ahead of the anticipated Notice of Funding Opportunity (NOFO) release, which is expected to be published on July 7, 2025. For further inquiries, potential applicants can contact Dr. Rajeev Gautam at rajeev.gautam@nih.gov or by phone at 301-761-5347.
    Consortia for Structure-based Immunogen Design for HIV (CSID-HIV)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Consortia for Structure-based Immunogen Design for HIV (CSID-HIV)" aimed at advancing research in the design of HIV immunogens that can induce broadly neutralizing antibody (bNAb) responses. This initiative seeks to support coordinated multidisciplinary efforts to overcome critical challenges in immunogen design, ultimately facilitating the development of safe and effective HIV therapeutics and vaccines. The funding will be provided through a cooperative agreement, with no cost-sharing or matching requirements, and is open to a diverse range of eligible applicants, including tribal governments, federal agencies, and community-based organizations. Interested parties should contact Dr. Stuart Z. Shapiro at sshapiro@niaid.nih.gov or call 240-292-6155 for further information. The estimated project start date is January 1, 2027, with a synopsis close date of April 14, 2026.
    Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is offering a funding opportunity titled "Priority HIV/AIDS Research" under the R01 grant mechanism. This initiative aims to stimulate research that aligns with NIH’s priorities regarding HIV/AIDS, particularly focusing on systemic complications such as metabolic, gastrointestinal, and kidney issues arising from HIV, while encouraging the incorporation of health-impeding social determinants of health into research proposals. The anticipated funding amount is $2 million, with plans to support 3 to 5 awards over five years, and applications are due starting May 7, 2025. Interested applicants can find more information and application guidelines at the NIH Grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Role of Defective Proviruses in HIV Persistence (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Role of Defective Proviruses in HIV Persistence (R01 Clinical Trial Not Allowed)" aimed at supporting research on the impact of defective HIV proviruses on persistence and pathogenesis during antiretroviral treatment. The objective is to characterize these defective proviruses in human samples, optimize assays to mitigate their influence, and study their effects on viral dynamics, which is crucial for improving HIV cure strategies and understanding chronic immune activation in treated individuals. Eligible applicants include a wide range of institutions, such as public and private nonprofits, higher education entities, and for-profits, with funding available up to $500,000 per year for projects lasting a maximum of five years. Interested parties should note that applications can be submitted starting in April 2025, and all inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Multidisciplinary Studies of HIV/AIDS and Aging," aimed at exploring the intersection of HIV and aging. This initiative seeks to enhance understanding of the biological, clinical, and socio-behavioral aspects of aging in the context of HIV infection, while also improving strategies for testing, prevention, and treatment of HIV-related health complications. Given the increasing number of older adults living with HIV, this research is crucial for addressing public health challenges and improving healthcare delivery across diverse populations. The funding supports exploratory research under the R21 mechanism, with a maximum budget of $275,000 for two years, and applications are due between May 2025 and January 2027. For more information, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-355.html.
    Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing HIV/AIDS Research within the Mission of the NIDCD," aimed at stimulating research related to HIV/AIDS and communication disorders. This initiative encourages applications that address high-priority research areas defined by the NIH Office of AIDS Research, focusing on the impact of HIV on hearing, balance, taste, smell, voice, speech, and language, with a budget limit of $275,000 for a two-year project period. Eligible applicants include a diverse range of institutions and organizations, and only low-risk clinical trials that do not require FDA oversight will be supported. Interested parties can find more information and application details at the NIH grants website, with deadlines for submissions ranging from May 2025 to January 2028.
    Advancing HIV/AIDS Research within the Mission of the NIDCD (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Advancing HIV/AIDS Research within the Mission of the NIDCD (R01 Clinical Trial Optional)" aimed at stimulating research related to communication disorders associated with HIV/AIDS. This initiative encourages innovative, hypothesis-driven research that addresses high-priority areas such as hearing, speech, and language, with a focus on low-risk clinical trials that do not require FDA oversight. Eligible applicants include a wide range of organizations, such as higher education institutions and community-based organizations, with funding available up to $499,999 per year for projects lasting up to five years. Interested parties should submit their applications by January 7, 2026, and can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the announcement page at https://grants.nih.gov/grants/guide/pa-files/PAR-23-099.html.
    High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)" aimed at supporting innovative research that addresses the intersection of HIV and substance use. This initiative invites applications from individual researchers and research teams to develop projects that can lead to new prevention, treatment, and care strategies for individuals affected by both conditions, with a requirement for a detailed research plan and preliminary data. A total budget of $3.0 million is available for funding one to two awards, with individual project budgets capped at $1.5 million per fiscal year, and applications are due by February 12, 2027. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to consult with NIDA program staff early in the application process.
    HIV Prevention and Alcohol (R01 Clinical Trials Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "HIV Prevention and Alcohol (R01 Clinical Trials Optional)" aimed at enhancing the HIV/AIDS prevention toolkit for populations impacted by alcohol use. This initiative seeks to integrate effective prevention and treatment interventions while developing and testing new strategies to address the behavioral and biological risks associated with HIV acquisition, particularly among high-risk groups such as men who have sex with men and transgender individuals. The anticipated funding for fiscal year 2025 is $2 million, with 2-4 awards expected, and applications must be submitted through Grants.gov by May 7, 2026. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information page at https://grants.nih.gov/grants/guide/pa-files/PAS-25-208.html.